Chongbiao Z. Huang

Tianjin Key Laboratory Of Digestive Cancer, Key Laboratory Of Cancer Prevention And Therapy
Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis.

Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis.

Journal: Signal transduction and targeted therapy

Published: January 03, 2026

CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway.

CLT-003 exerts anti-tumor activity in pancreatic cancer by blocking the PI3K/AKT/HIF-1α pathway.

Journal: Cancer biology & medicine

Published: September 30, 2025

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.

Senescent Cancer-Associated Fibroblasts Drive Early-Stage Lymph Node Metastasis in Pancreatic Cancer through Lactate-Mediated Metabolic-Epigenetic Rewiring.

Journal: Cancer discovery

Published: September 18, 2025

Molecular mechanisms and clinical insights of benzo[a]pyrene-related lung adenocarcinoma: New discoveries in multi-scale approaches.

Molecular mechanisms and clinical insights of benzo[a]pyrene-related lung adenocarcinoma: New discoveries in multi-scale approaches.

Journal: Ecotoxicology and environmental safety

Published: July 08, 2025

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

Journal: Gut

Published: June 30, 2025

Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells.

Tumor-Derived Interleukin 35 Promotes Fibrosis in the Tumor Microenvironment of Pancreatic Cancer by Activating Pancreatic Stellate Cells.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: May 21, 2025

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Trogocytosis-orchestrated CLDN18.2-"dressed" CD8+ T cells drive pancreatic cancer progression via glucose metabolic reprogramming-induced cytotoxicity debilitation and systematic immune senescence cascade.

Journal: Gut

Published: May 05, 2025

A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma.

A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma.

Journal: Cell reports. Medicine

Published: January 29, 2025

Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity.

Prime editor with rational design and AI-driven optimization for reverse editing window and enhanced fidelity.

Journal: Nature communications

Published: January 23, 2025

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells.

Nociceptor neurons promote PDAC progression and cancer pain by interaction with cancer-associated fibroblasts and suppression of natural killer cells.

Journal: Cell research

Published: September 17, 2024

The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.

The nuclear condensates of ESE3/EHF induce cellular senescence without the associated inflammatory secretory phenotype in pancreatic ductal adenocarcinoma.

Journal: Cancer letters

Published: September 03, 2024

Clinical effect of Almonertinib in treating epidermal growth factor receptor mutation-positive residual ground-glass opacities after stage I lung cancer resection.

Clinical effect of Almonertinib in treating epidermal growth factor receptor mutation-positive residual ground-glass opacities after stage I lung cancer resection.

Journal: American journal of translational research

Published: July 13, 2024

Showing 1-12 of 69

Last Updated: 09/26/2026